Increased Drug Outsourcing To China, India A Concern In U.S.
This article was originally published in PharmAsia News
Executive Summary
America's increasing reliance on drugs produced in other countries, primarily China and India, is causing concern among U.S. lawmakers and some health experts. They note that no antibiotics are being made in the United States any more and the active pharmaceutical ingredients for dozens of other vital drugs also come from those two countries. U.S. FDA records show that of 1,154 production plants listed in generics applications, 43 percent were in China, 39 percent in India. Sen. Sherrod Brown, D-Ohio, cited a lack of regulations covering outsourcing as a problem at a time of concern about bioterrorism and counterfeits. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.